Nucleai Blog How AI and Spatial Biomarkers Are Transforming Antibody-Drug Conjugate Development

Spatial biomarkers are making their mark on oncology drug development. By quantifying the spatial heterogeneity within tumor tissues, predictive spatial scores can help identify relationships between biomarker expression patterns and therapeutic outcomes. The scores also enable researchers to assess the spatial relationships critical to the mechanisms of antibody-drug conjugates (ADCs), such as the bystander effect, [...]The post How AI and Spatial Biomarkers Are Transforming Antibody-Drug Conjugate Development appeared first on Nucleai.